Patients With Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s612, 2025. DOI: 10.25251/m9gw3y80. Disponível em: https://skin.dermsquared.com/skin/article/view/3814. Acesso em: 19 apr. 2026.